# ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy

Study · id `cardio:ct-nct06580717` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06580717](<https://clinicaltrials.gov/study/NCT06580717>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT06580717

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 200 participants.

## Technical summary

Registry record NCT06580717. Randomized; single masking; primary purpose treatment. Start 2024-10-15 (actual); primary completion 2026-11-30 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT06580717, source copy `cardio:ctgov-nct06580717-2024-11-08`, retrieved 2026-10-31)
- Started: 2024-10-15 (actual) (ClinicalTrials.gov record NCT06580717, source copy `cardio:ctgov-nct06580717-2024-11-08`, retrieved 2026-10-31)
- Primary completion: 2026-11-30 (anticipated) (ClinicalTrials.gov record NCT06580717, source copy `cardio:ctgov-nct06580717-2024-11-08`, retrieved 2026-10-31)
- Completion: 2026-11-30 (anticipated) (ClinicalTrials.gov record NCT06580717, source copy `cardio:ctgov-nct06580717-2024-11-08`, retrieved 2026-10-31)
- Countries: South Korea (ClinicalTrials.gov record NCT06580717, source copy `cardio:ctgov-nct06580717-2024-11-08`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06580717-2024-11-08`, retrieved 2026-10-31)

## The registry's words

- Brief title: ENavogliflozin DElivering Alleviation of Ventricular Diastolic Dysfunction in nonObstRuctive Hypertrophic CardioMyopathy
- Condition: Nonobstructive Hypertrophic Cardiomyopathy
- Intervention (Drug): enavogliflozin 0.3mg
- Intervention (Drug): enavogliflozin Placebo
- Lead sponsor: Yonsei University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`)
- Registry condition terms include this condition: Hypertrophic cardiomyopathy (`cardio:hypertrophic-cardiomyopathy`)
- Registry lists this organization as the lead sponsor: Yonsei University (`cardio:org-yonsei-university`)

## Provenance

Content hash: 558d82032961b4dd4d4f8ed3485fb7d20d31e4ff894b90c8f39f02aadd134416
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
